Page last updated: 2024-08-21

pyrazines and Bone Marrow Neoplasms

pyrazines has been researched along with Bone Marrow Neoplasms in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Iwai, F; Kato-Ogura, A; Onaka, T; Otsuka, Y; Yonezawa, A	1
Buchner, K; Eulberg, D; Facchetti, F; Ghobrial, IM; Klussmann, S; Kruschinski, A; Lonardi, S; Maasch, C; Maiso, P; Mishima, Y; Moschetta, M; Purschke, WG; Reagan, MR; Roccaro, AM; Rossi, G; Sacco, A; Ungari, M; Vater, A; Vonhoff, S; Zboralski, D; Zöllner, S	1
Birner, A; Boral, A; Diener, JG; Esseltine, DL; Ghobrial, IM; Ioakimidis, L; Keogh, GP; Matous, J; Mattern, J; Myers, TJ; Nelson, M; Patterson, CJ; Sheehy, P; Soumerai, JD; Treon, SP; Willen, M	1
Richardson, P	1

Trials

1 trial(s) available for pyrazines and Bone Marrow Neoplasms

Article	Year
Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-10, Volume: 27, Issue:23 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood Viscosity; Bone Marrow Neoplasms; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Hematocrit; Herpes Zoster; Humans; Immunoglobulin M; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Count; Pyrazines; Rituximab; Treatment Outcome; Waldenstrom Macroglobulinemia	2009

Article

Year

Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-10, Volume: 27, Issue:23

Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood Viscosity; Bone Marrow Neoplasms; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Hematocrit; Herpes Zoster; Humans; Immunoglobulin M; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Count; Pyrazines; Rituximab; Treatment Outcome; Waldenstrom Macroglobulinemia

2009

Other Studies

3 other study(ies) available for pyrazines and Bone Marrow Neoplasms

Article	Year
A case report of combined treatment of gilteritinib and LH-RH agonist for Fms-related tyrosine kinase 3 receptor mutation-positive acute myeloid leukemia and bone marrow metastasis of prostate cancer. Annals of hematology, 2022, Volume: 101, Issue:2 Topics: Aniline Compounds; Bone Marrow Neoplasms; fms-Like Tyrosine Kinase 3; Gonadotropin-Releasing Hormone; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Oligopeptides; Prostatic Neoplasms; Pyrazines	2022
SDF-1 inhibition targets the bone marrow niche for cancer therapy. Cell reports, 2014, Oct-09, Volume: 9, Issue:1 Topics: Animals; Bone Marrow; Bone Marrow Neoplasms; Boronic Acids; Bortezomib; Chemokine CXCL12; Female; Gene Knockdown Techniques; Humans; Male; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Metastasis; Oligonucleotides; Polyethylene Glycols; Pyrazines	2014
Newer treatment options for patients in first relapse. From the Multiple Myeloma Research Foundation. Oncology (Williston Park, N.Y.), 2006, Volume: 20, Issue:6 Topics: Antineoplastic Agents; Bone Marrow Neoplasms; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Drug Therapy, Combination; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Transplantation, Autologous; Treatment Outcome	2006